Jianguang Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jianguang Xu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Cheng Chen
1 shared publication- Hanyue Xu1 shared publication
Jiahui Jiang
1 shared publication- Li Cui
Shanghai Key Laboratory of Veterinary Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
1 shared publication Lihui Wang
Department of Colorectal Surgery The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital Zhejiang Quzhou China
1 shared publicationMengyuan Ma
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38
A Janus polydopamine nanomotor hydrogel enables enhanced tumor penetration and potent synergistic photothermal-photodynamic therapy
- 20 May 2026
- Published by Elsevier in Materials Today Bio
- Vol. 38
Open AccessA Janus polydopamine nanomotor hydrogel enables enhanced tumor penetration and potent synergistic photothermal-photodynamic therapy
- Open Access
- 31 March 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (10) , 11641-11650
Impacts of pre‐existing diabetes mellitus on colorectal cancer in a mice model
Background: Although diabetes mellitus (DM) is regarded as a risk factor of colorectal cancer (CRC), the impacts of pre‐existing DM on CRC without drug intervention remain unknown. The purpose of this study was to investigate and analyze the effects of diabetes mellitus (DM) on colorectal cancer (CRC). And, to further explore the influencing factors and the mechanisms of DM affects CRC progression.Methods: In this study, we investigated the effects of DM on CRC progression in a streptozotocin‐induced DM mice model. Furthermore, we evaluated the change of T cells levels using flow cytometry and indirect immunofluorescence. We assessed the alternation of gut microbiome and the transcriptional response using 16s rRNA sequencing and RNA‐seq.Results: Results showed that the mice survival time was significantly decreased in CRC complicated with DM group (DM‐CRC), compared with only tumor bearing mice (CRC group). Furthermore, we found that DM could affect the immune response by changing the infiltration of CD4+ T cells, CD8+ T cells and mucosal‐associated invariant T cell (MAIT) in the CRC progression. In addition, DM could induce gut microbiome dysbiosis and change the transcriptional response in CRC complicated with DM.Conclusion: For the first time, the effects of DM on CRC were systematically characterized in a mice model. Our findings highlight the effects of pre‐existing DM on CRC, and these findings should facilitate further studies in exploring and developing potentially targeted therapy for CRC in diabetic patients. Our results suggest that the effects induced by DM should be considered in the treatment for CRC complicated with DM patients.
- 31 March 2023
- Published by Wiley in Cancer Medicine
- Vol. 12 (10) , 11641-11650
Open AccessImpacts of pre‐existing diabetes mellitus on colorectal cancer in a mice model
Background: Although diabetes mellitus (DM) is regarded as a risk factor of colorectal cancer (CRC), the impacts of pre‐existing DM on CRC without drug intervention remain unknown. The purpose of this study was to investigate and analyze the effects of diabetes mellitus (DM) on colorectal cancer (CRC). And, to further explore the influencing factors and the mechanisms of DM affects CRC progression.Methods: In this study, we investigated the effects of DM on CRC progression in a streptozotocin‐induced DM mice model. Furthermore, we evaluated the change of T cells levels using flow cytometry and indirect immunofluorescence. We assessed the alternation of gut microbiome and the transcriptional response using 16s rRNA sequencing and RNA‐seq.Results: Results showed that the mice survival time was significantly decreased in CRC complicated with DM group (DM‐CRC), compared with only tumor bearing mice (CRC group). Furthermore, we found that DM could affect the immune response by changing the infiltration of CD4+ T cells, CD8+ T cells and mucosal‐associated invariant T cell (MAIT) in the CRC progression. In addition, DM could induce gut microbiome dysbiosis and change the transcriptional response in CRC complicated with DM.Conclusion: For the first time, the effects of DM on CRC were systematically characterized in a mice model. Our findings highlight the effects of pre‐existing DM on CRC, and these findings should facilitate further studies in exploring and developing potentially targeted therapy for CRC in diabetic patients. Our results suggest that the effects induced by DM should be considered in the treatment for CRC complicated with DM patients.